Popular terms

[SEARCH]

Platelet topics
Growth Factor
Fibroblast
Nanoparticle
Autologous
Leukocytes
Circulation
Transforming Growth Factor
Therapeutical
Platelet Derived Growth Factor
Bone Morphogenetic Protein
Endothelial
Recombinant
Stem Cells
Respiratory System
Dispensing System

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Platelet patents



      
           
This page is updated frequently with new Platelet-related patent applications. Subscribe to the Platelet RSS feed to automatically get the update: related Platelet RSS feeds. RSS updates for this page: Platelet RSS RSS


Cd31 peptides

Assistance Publique - Hopitaux De Paris

Cd31 peptides

Passive separation of whole blood

Halcyon Biomedical

Passive separation of whole blood


Date/App# patent app List of recent Platelet-related patents
07/23/15
20150203819 
 Production of red blood cells and platelets from stem cells patent thumbnailProduction of red blood cells and platelets from stem cells
This disclosure provides methods of making a megakaryocyte-erythroid progenitor cell (mep), comprising differentiating a mep precursor cell into a mep in culture in the presence of an aryl hydrocarbon receptor (ahr) modulator. In some embodiments the ahr modulator is an ahr antagonist.
Trustees Of Boston University


07/23/15
20150203536 
 Cd31 peptides patent thumbnailCd31 peptides
The present invention provides peptides corresponding to fragments of cd31 that inhibit platelet and leukocyte activation, and to their use in the treatment of thrombotic disease. These peptides find use as therapeutic agents in the treatment of inflammatory diseases and thrombotic diseases such as atherothrombosis, in particular when immobilised onto solid supports..
Assistance Publique - Hopitaux De Paris


07/23/15
20150202356 
 Passive separation of whole blood patent thumbnailPassive separation of whole blood
Described are systems, methods, and kits for compression sedimentation and whole blood separation. For example, a compression sedimentation system may include a compression stage configured to accept a flexible reservoir configured to contain a liquid mixture.
Halcyon Biomedical, Incorporated


07/23/15
20150202264 
 Platelet activation and growth factor release using electric pulses patent thumbnailPlatelet activation and growth factor release using electric pulses
Methods and systems for releasing growth factors are disclosed. In certain embodiments, a blood sample is exposed to a sequence of one or more electric pulses to trigger release of a growth factor in the sample.
General Electric Company


07/16/15
20150198620 
 Anti-platelet response and reactivity test using synthetic collagen patent thumbnailAnti-platelet response and reactivity test using synthetic collagen
The present invention provides platelet aggregation tests using synthetic, self-assembling type i human collagen, methods of measuring an individual's platelet anti-platelet medication sensitivity and residual platelet activity status when the individual is on a an anti-platelet medication and kits useful in the assays and methods.. .
Jnc Corporation


07/16/15
20150196513 
 Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent patent thumbnailMethod of treating cardiovascular events using colchicine concurrently with an antiplatelet agent
Methods of treating and/or preventing a cardiovascular event in a patient, the method comprising orally administering a colchicine to a patient who is receiving concurrent treatment with at least one antiplatelet agent, thereby treating and/or preventing the cardiovascular event in the patient are provided.. .
Murray And Poole Enterprises Limited


07/09/15
20150194246 
 Permanent magnet, motor, and generator patent thumbnailPermanent magnet, motor, and generator
A permanent magnet includes: a composition expressed by a composition formula: rpfeqmrcutco100-p-q-r-t (r is at least one element selected from rare-earth elements, m is at least one element selected from zr, ti, and hf, 10.5≦p≦12.5 at %, 23≦q≦40 at %, 0.88≦r≦4.5 at %, 4.5≦t≦10.7 at %); and a metal structure containing a cell phase having a th2zn17 crystal phase, a cell wall phase, an m-rich platelet phase formed vertically to a c-axis of the th2zn17 crystal phase, and a cu-rich platelet phase formed along the m-rich platelet phase.. .
Kabushiki Kaisha Toshiba


07/09/15
20150191734 
 Adipocyte-specific constructs and methods for inhibiting platelet-type 12 lipoxygenase expression patent thumbnailAdipocyte-specific constructs and methods for inhibiting platelet-type 12 lipoxygenase expression
The present invention is directed to constructs, compositions and methods for modulating platelet-type 12 lipoxygenase (12-lo) in adipose tissue in vivo. Specifically, the invention provides constructs encoding expression-inhibiting oligonucleic acids, e.g.
The Medical Research Fund At The Tel-aviv Sourasky Medical Center


07/09/15
20150191455 
 Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto patent thumbnailPyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
Pyrazole derivatives of formula ia and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (sle); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (copd)..
Arena Pharmaceuticals, Inc.


07/09/15
20150191454 
 Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto patent thumbnailModulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
Cyclohexane derivatives of formula ia and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (sle); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (copd)..

07/09/15
20150190468 

Methods for creating and using platelet extracts


This invention provides processes for creating and stabilizing extracts of platelets possessing improved properties for tissue engineering and cell culture applications relative to other methods, that can be made without the use of freeze lysis, the resulting compositions, and methods for using them.. .

07/09/15
20150190253 

Coated devices and methods of making coated devices that reduce smooth muscle cell proliferation and platelet activity


The present invention relates generally to the maintenance of blow flood using drug eluting stents and/or other coated medical devices to increased length of time of blood flow. Further, the present invention relates to drug-releasing coated devices for reducing smooth muscle cell proliferation and platelet activity to further limit restenosis utilizing resveratrol and quercetin, polyphenols that are linked to the cardioprotection of red wine consumption.
Nanocopoeia, Inc.


07/02/15
20150185214 

Methods and kits for measuring von willebrand factor


Methods and kits for measuring levels of von willebrand factor function in a sample without using a platelet aggregation agonist, such as ristocetin, comprising recombinant glycoprotein ibα having a combination of g233v, d235y and m239v mutations and an agent to detect a complex between the recombinant glycoprotein ibα and von willebrand factor.. .
The Medical College Of Wisconsin, Inc.


07/02/15
20150185210 

Platelet measurement reagent, platelet measurement reagent kit, and platelet measurement method


A reagent for measuring platelets comprising nile blue hydrogensulfate, or nile blue and an acid, a reagent kit for measuring platelets comprising the reagent for measuring platelets, and a method for measuring platelets using the reagent or reagent kit.. .
Sysmex Corporation


07/02/15
20150183995 

Pearlescent pigments coated with mixed inorganic/organic layers and the production thereof


The invention relates to platelet-shaped pearlescent pigments that are coated with at least one mixed inorganic/organic layer for improving their application properties, and of these, particularly their mechanical properties, and to methods for the production thereof and to the use thereof. The said mixed inorganic/organic layer comprises at least one at least partially crosslinked inorganic metal-oxide component and an organic component.
Eckart Gmbh


06/25/15
20150180073 

Ion-conducting membrane


An ion-conducting membrane includes: (i) a first ion-conducting layer including one or more first ion-conducting polymers; and (ii) a barrier layer including graphene-based platelets.. .
Johnson Matthey Fuel Cells Limited


06/25/15
20150174712 

Graphene nanoplatelet metal matrix


A metal matrix composite is disclosed that includes graphene nanoplatelets dispersed in a metal matrix. The composite provides for improved thermal conductivity.
The Boeing Company


06/25/15
20150174591 

Centrifuge


Centrifuges are useful to, among other things, remove red blood cells from whole blood and retain platelets and other factors in a reduced volume of plasma. platelet rich plasma (prp) and or platelet poor plasma (ppp) can be obtained rapidly and is ready for immediate injection into the host.
Kensey Nash Corporation


06/25/15
20150174313 

Blood component separation device


The object of the invention is to provide a blood separation device that can reduce the total time for drawing blood to obtain high-concentration platelet liquid, thereby reducing the binding time of the blood donor. The device includes a temporary storage bag (y2) (also serves as a buffy coat bag) which is a whole blood bag for storing whole blood drawn from a blood donor.
Terumo Kabushiki Kaisha


06/25/15
20150174221 

Systems, compositions, and methods for transplantation


Systems and methods for purification and concentration of autologous alpha-2-macroglobulin (a2m) from whole blood are provided. Also provided are diagnostic methods for identifying sites in the synovial joints, spine, tendons or ligaments for treatment of pain, degeneration, or inflammation with autologous a2m.
Cytonics Corporation


06/25/15
20150174171 

Compositions and methods for the treatment and alleviation of bone and cartilage diseases or injuries and hair loss


The present invention provides pharmaceutical compositions, and methods of preparation and use for the treatment, prevention or alleviation of bone and cartilage diseases or injuries and hair loss. The present invention discloses a method and a pharmaceutical composition comprising mesenchymal stem cells, platelets, activating factors and scaffolding materials for the treatment, prevention, or alleviation of bone diseases, bone injuries or hair loss, and a method and a pharmaceutical composition further comprising dexamethasone for the treatment, prevention, or alleviation of cartilage diseases or injuries..

06/25/15
20150174170 

Compositions and methods for the treatment and alleviation of bone and cartilage diseases or injuries and hair loss


The present invention provides pharmaceutical compositions, and methods of preparation and use for the treatment, prevention or alleviation of bone and cartilage diseases or injuries and hair loss. The present invention discloses a method and a pharmaceutical composition comprising mesenchymal stem cells, platelets, activating factors and scaffolding materials for the treatment, prevention, or alleviation of bone diseases, bone injuries or hair loss, and a method and a pharmaceutical composition further comprising dexamethasone for the treatment, prevention, or alleviation of cartilage diseases or injuries..

06/18/15
20150166760 

Metal effect pigments comprising a mixed inorganic/organic layer, the production of such metal effect pigments, and use thereof


The invention relates to metallic effect pigments with coating, comprising a platelet-shaped substrate, where the coating comprises at least one hybrid inorganic/organic layer, the hybrid layer having at least partly an inorganic network that has one or more inorganic oxide components, and having at least one organic component, the organic component being at least partly an organic oligomer and/or polymer which is covalently bonded at least partly to the inorganic network via one or more organic network formers. The invention further relates to a method of producing these metallic effect pigments, and to their use..
Eckart Gmbh


06/18/15
20150164956 

Muscle-derived cells (mdcs) for treating muscle- or bone-related injury or dysfunction


The present invention provides muscle-derived cells, preferably myoblasts and muscle-derived stem cells, genetically engineered to contain and express one or more heterologous genes or functional segments of such genes, for delivery of the encoded gene products at or near sites of musculoskeletal, bone, ligament, meniscus, cartilage or genitourinary disease, injury, defect, or dysfunction. Ex vivo myoblast mediated gene delivery of human inducible nitric oxide synthase, and the resulting production of nitric oxide at and around the site of injury, are particularly provided by the invention as a treatment for lower genitourinary tract dysfunctions.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education


06/11/15
20150160214 

Quantitation of cellular adhesion dynamics across immobilized receptors under rheological shear flow


The present invention includes an apparatus and methods for measuring cell or platelet adhesion comprising: a rheological shear flow surface coated with an agent that provides cell or platelet adhesion; a detector to track the transit of cells or platelets on the surface under shear flow; and a processor that calculates both a pause time and a roll time of platelets, wherein the processor determines a median and a mean pause time and a median and a mean roll time of cells or platelets and compares them to cells or platelets having at least one of: no cell adhesion dysfunction, a mild adhesion dysfunction, or a severe adhesion dysfunction, between a cell surface adhesion molecule on the cell or platelet and the agent, wherein the processor provides a real-time, quantitative measurement of a dynamic range of cell or platelet adhesion.. .
Mayo Foundation For Medical Education And Research


06/11/15
20150160213 

Compositions and methods for assaying platelet reactivity and treatment selection


Compositions and methods are provided for determining platelet reactivity where the levels of fcγriia on the surface of platelets is measured and if the levels of fcγriia are greater than a reference value, the platelets have enhanced reactivity.. .
The University Of Vermont And State Agriculture College


06/04/15
20150155340 

Dual-mode pixels including emissive and reflective devices, and dual-mode display using the pixels


Provided is a dual-mode display including a substrate and a plurality of sub-pixels on the substrate, in which each sub-pixel includes an emissive device, a color selection reflector disposed on one side of the emissive device, and an optical shutter disposed on another side of the emissive device, wherein the emissive device includes a cathode and an anode, and the cathode and the anode include a carbon-based material including graphene sheets, graphene flakes, and graphene platelets, and a binary or ternary transparent conductive oxide including indium oxide, tin oxide, and zinc oxide.. .
Electronics And Telecommunications Research Institute


06/04/15
20150152314 

Cement composition comprising nano-platelets


A method of cementing a subterranean formation includes providing a cement composition comprising cementitious material, aqueous base fluid, graphene nano-platelets, and a dispersant; introducing the cement composition into a subterranean formation; and allowing the cement composition to set in the subterranean formation. Upon setting, the cement has at least one of enhanced compressive and tensile strength; reduced permeability; restricted penetration of carbon dioxide; and combinations thereof relative to an equivalent cement without graphene nano-platelets.
Halliburton Energy Services, Inc.


06/04/15
20150152111 

Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition


The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.. .
Astrazeneca Uk Limited


06/04/15
20150150942 

Methods for extracting platelets and compositions obtained therefrom


This invention provides methods for extracting platelets, compositions obtained therefore, and methods for using the same.. .
The Regents Of The University Of Colorado, A Body Corporate


05/28/15
20150148901 

Apparatus and breast reconstruction and augmentation using an autologous platelet-rich fibrin matrix


Described herein are systems and methods for soft tissue reconstruction and augmentation using a platelet-rich fibrin matrix. In one embodiment the system of the present invention includes a blood collection apparatus capable of drawing blood from a patient, a matrix preparation container configured to hold a patient's blood while the blood is separated and coagulated to form a platelet-rich fibrin matrix therein, and a matrix delivery device configured to receive the matrix preparation container therein and compress and force the platelet-rich fibrin matrix out of the matrix preparation container and into the patient.

05/28/15
20150148385 

Pharmaceutical composition containing a compound having a thrombopoietin receptor agonistic activity


“when the platelet count has increased by a certain amount and reached to a sufficient level of the platelet count during administration of a pharmaceutical composition containing a compound having a thrombopoietin receptor agonistic activity, administration of the pharmaceutical composition is discontinued thereafter”.. .

05/28/15
20150147300 

Methods of mediating macrophage phenotypes


Methods of inducing a polarization of macrophages. The method includes obtaining a blood fraction, fractionating the blood fraction to produce a blood fraction, and contacting the blood fraction with a source of macrophages.
Biomet Biologics, Llc


05/28/15
20150147228 

Permanent magnet, and motor and generator using the same


In one embodiment, a permanent magnet has a composition represented by a composition formula: rpfeqmrcusco100-p-q-r-s, where r is a rare earth element, m is at least one element selected from zr, ti, and hf, p is 8.0 atomic % or more and 13.5 atomic % or less, q is 25 atomic % or more and 40 atomic % or less, r is 0.88 atomic % or more and 7.2 atomic % or less, and s is 3.5 atomic % or more and 13.5 atomic % or less, and a metallic structure including a cell phase having a th2zn17 crystal phase, a cell wall phase, and a platelet phase existing along a c plane of the th2zn17 crystal phase. An average thickness of the platelet phase is in a range of from 2.5 nm to 20 nm..
Kabushiki Kaisha Toshiba


05/21/15
20150141477 

Pyrazole derivatives and their use as lpar5 antagonists


The present invention relates to compounds of the formula (i), wherein the residues r1 to r5, v, g and m have the meanings indicated in the claims. The compounds of the formula (i) are valuable pharmacologically active compounds for use in the treatment of diverse disorders, for example cardiovascular disorders like thromboembolic diseases or restenoses.
Sanofi


05/21/15
20150141471 

Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation


The present invention relates to compounds of the formula (i), wherein the residues r1 to r6, v, g and m have the meanings indicated in the claims. The compounds of the formula i are valuable pharmacologically active compounds for use in the treatment of diverse disorders, for example cardiovascular disorders like thromboembolic diseases or restenoses.
Sanofi


05/21/15
20150141332 

Methods for diagnosing osteoarthritis


Methods for managing osteoarthritis, in a human or other mammalian subject, comprising the measurement of certain cytokines and growth factors in a tissue sample of a subject, including one or more of platelet-derived growth factor ab (pdgf-ab), platelet-derived growth factor bb (pdgf-bb), and epidermal growth factor (egf). Tissue samples may be whole blood, blood fractions, urine, saliva, and synovial fluid.
Biomet Biologics, Llc


05/21/15
20150140120 

Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics


Materials and methods are provided for producing and using aptamers useful as oncology therapeutics capable of binding to pdgf, pdgf isoforms, pdgf receptor, vegf, and vegf receptor or any combination thereof with great affinity and specificity. The compositions of the present invention are particularly useful in solid tumor therapy and can be used one or in combination with known cytotoxic agents for the treatment of solid tumors.
Archemix Llc


05/14/15
20150135344 

Methods of modulating thrombocytopenia and modified transgenic pigs


The application provides methods of modulating platelet uptake by liver sinusoidal endothelial cells and of modulating thrombocytopenia. Transgenic pigs modified to bind fewer platelets are provided..

05/14/15
20150133446 

Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation


The present invention provides imidazothiadiazole compounds of formula (i) wherein a, b, d, rx, r1, r2, r3, x1, x2 and s are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments..

05/14/15
20150132261 

Treatment of thrombocytopenia using orally administered interferon


An interferon composition is provided for enhancing the platelet count, reducing the recurrence rate of hepatitis, and/or improving the social function of hepatitis patients. The method comprises administering a low dose of ifn (about 5 iu to about 2500 iu of ifn-alpha) to a patient in need thereof.

05/14/15
20150128935 

Inhalation systems, breathing apparatuses, and methods


Examples of the invention include inhalation systems, breathing apparatuses, and methods for administering a solution by inhalation to a patient. Example breathing apparatuses described herein may be configured to minimize loss of the solution to the environment.

05/07/15
20150126527 

Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto


The present invention relates to amide derivatives of formula (xiiia) and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah); idiopathic pah; familial pah; pah associated with a collagen vascular disease, a congenital heart disease, portal hypertension, hiv infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (pvod) or pulmonary capillary hemangiomatosis (pch); pah with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack, angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (sle); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (copd)..

05/07/15
20150125436 

Process, tube and device for the preparation of wound healant composition


The present invention is related to the field of tissue regeneration. It concerns more particularly new processes, tubes and devices for thrombin, platelet concentrate and wound healant preparations, alone or in combination with cell extracts, cell compositions and uses thereof..

05/07/15
20150125430 

Compositions and methods for inducing thrombopoiesis


Methods of inducing thrombopoiesis and/or treating thrombocytopenia in a subject are provided. Accordingly there is provided a method comprising contacting stem cells with a differentiation potential towards platelets or hematopoietic progenitor cells derived therefrom with livin, thereby inducing thrombopoiesis.
Hadasit Medical Research Services And Development Ltd.


05/07/15
20150122713 

Prp obtaining device


A platelet rich plasma (prp) obtaining device includes a container attached to a receptacle for allowing a material in the receptacle to flow into the container, a piston engaged in the receptacle for forcing the material to partially flow into the container, a housing slidably engaged in the container and having a space and having a tube extended in the housing, the tube includes a bore communicating with a compartment of the container, but offset from the space of the housing, and a check valve is attached to the housing for limiting the material to flow only from the container to the housing, and for preventing the material from flowing backward from the housing into the container.. .
Yung Kang Medical Device & Technologic Co., Ltd.


04/30/15
20150119495 

Preparation of rubber composition containing graphite platelets and tire with component


Preparation of a rubber composition containing a dispersion of aligned exfoliated graphite platelets. Such rubber composition is prepared by a method comprised of a sequential combination of concentrated solvent or dry masterbatching of elastomer and exfoliated graphite platelets, followed by blending the masterbatch (after removing the solvent from the solvent based masterbatch) with additional elastomer(s) and then followed by processing the resulting rubber composition to align the dispersed exfoliated graphite platelets in a substantially parallel relation to each other.
The Goodyear Tire & Rubber Company


04/30/15
20150119390 

Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation


The present invention provides imidazothiadiazole compounds of formula (i); wherein w, y, r0, r2, r4, ra, rb, x1, x2, x3 and x4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders..
Universite De Monteal


04/30/15
20150118210 

Composition for enhancing cell engraftment and homing properties containing prp as active ingredient


The present invention provides a composition for enhancing cell engraftment and homing properties, containing platelet-rich plasma (prp) as an active ingredient. The present invention provides a method for improving cell engraftment and homing properties, comprising the step of treating in vitro isolated cells with a composition containing prp as an active ingredient.
Snu R&db Foundation


04/30/15
20150118109 

Component preparation system


Disclosed herein are centrifuge-free self-contained systems for aseptically separating components of whole blood comprising at least one cassette for receiving whole blood; at least one red blood cell exclusion filter; at least one leukocyte reduction filters; at least one platelet exclusion filter; a plurality of product cassettes; and optionally a plurality of pumps and valves; and wherein the filters, pumps, valves, and cassettes are fluidly connected by tubing and the system does not include a centrifuge. Also disclosed are methods for obtaining blood components using the system..
New York Blood Center, Inc.


04/23/15
20150111889 

Benzo[1,3]dioxine derivatives and their use as lpar5 antagonists


The present invention relates to compounds of the formula (i), wherein the residues a, r1 to r5, z1 and z2 have the meanings indicated in the claims. The compounds of the formula (i) are valuable pharmacologically active compounds for use in the treatment of diverse disorders, for example cardiovascular disorders like thromboembolic diseases or restenoses.
Sanofi


04/23/15
20150111777 

Biomarker for early neurodegeneration detection


The present invention relates to compositions, methods, and kits that can be used to assess neurodegeneration associated diseases and conditions in a subject by detecting the level of tdp-43 protein in platelets. The compositions, methods, and kits are suitable for neurodegeneration associated disease diagnosis, prognosis and treatment evaluation..
Kansas City University Of Medicine And Biosciences


04/16/15
20150105338 

Therapeutic compositions comprising phenolic acids for treating conditions related to inappropriate platelet aggregation


The invention provides compositions comprising a therapeutically effective amount of a compound of general formula (i): wherein r1, r2 and r3 may be independently selected from h, oh and ome; wherein x is c1 or c2 and wherein for c2 each carbon is linked by a single or multiple bond (preferably a double bond) and is substituted with one or more h or oh, for use as a medicament for treating or preventing the development of medical conditions characterised by inappropriate platelet aggregation. The compositions of the invention may be used to maintain heart health by reducing platelet aggregation; benefit the circulation; and/or normalize or otherwise benefit blood flow..
Provexis Natural Products Limited


04/16/15
20150104436 

Application and pharmaceutical composition of preactivated and disaggregated shape-changed platelets


Preactivated and disaggregated shape-changed platelets, fixed shape-changed platelets, and a pharmaceutical composition thereof are used for treating acute and emergent inflammatory disease in a dosage of 1×106 to 1×108. Activated platelets release and transfer adhesion factors to the surface of platelet cells, and trap stromal vascularity inflammatory cells from inflammated and damaged place, and the stromal vascularity inflammatory cells are eliminated through the circulatory system to alleviate inflammation.
Chang Gung Medical Foundation, Linkou Branch


04/16/15
20150101995 

Device and extracting high-concentration plasma from whole blood


Disclosed are a device and method of extracting high-concentration plasma from whole blood. The device comprises: a first syringe; a centrifugation tube that is connected to the first syringe in order to centrifuge whole blood received in the first syringe; a cap that is connected to the first syringe in order to re-centrifuge plasma collected in the first syringe by centrifugation of the whole blood; and a membrane filter comprising: a body that is cylindrical in shape and has a pair of spaced inlets to which the first syringe and a second syringe are to be respectively connected; a hollow membrane included in the body; and a first space formed between the body and the membrane and serving to collect components that passed through the membrane.

04/09/15
20150099716 

Maintenance of platelet inhibition during antiplatelet therapy


A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis.
The Medicines Company


04/09/15
20150099298 

Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof


The present invention relates to antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.. .
Bayer Pharma Aktiengesellschaft


04/09/15
20150098939 

Novel antagonist antibodies and their fab fragments against gpvi and uses thereof


The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein glycoprotein vi (gpvi) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a gpvi depletion phenotype.
Sanofi


04/02/15
20150094298 

Inhibitors of protein kinases


The present invention is directed to compounds of formula i-ii and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof which are inhibitors of syk and/or jak kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or jak kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or jak kinase activity, such as undesired thrombosis and non hodgkin's lymphoma..
Portola Pharmaceuticals, Inc.


04/02/15
20150094297 

Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation


The present invention provides thiazole compounds of formula i wherein w, y, r0, r2, r4, r5, r6, r7, x1, x2, x3 and x4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders..
Universite De Montreal


04/02/15
20150093770 

Method and device for the determination of platelet function under flow conditions


The invention lies in the area of platelet function diagnostics and relates to a method for the determination of platelet function under flow conditions as well as a device for the implementation of this method. The method is particularly suitable for the determination of the effect of clopidogrel and of other p2y(12) antagonists with antithrombotic activity as well as the determination of p2y(1) antagonists with antithrombotic activity..
Siemens Healthcare Diagnostics Products Gmbh


04/02/15
20150093543 

Blood compatible surfaces


The disclosure features blood compatible articles and methods of making the articles. The methods include providing a substrate and forming a rough surface on the substrate.
Teijin Limitied


04/02/15
20150093390 

Humanized and chimeric anti-factor bb antibodies and uses thereof


A method of inhibiting complement activation mediated by bb inhibitors in a subject includes administering a bb inhibitor to the subject to inhibit at least one of bb binding to factors b and properdin, inhibit c3 cleavage, inhibit the activation of neutrophils, monocytes, platelets, and endothelium; or inhibit the formation of c3a, c5a, and mac.. .
Novelmed Theraperutics, Inc.


03/26/15
20150083973 

Systems, devices, and/or methods for solar cells comprising a light amplification element


Certain exemplary embodiments can provide a method, which can comprise fabricating a system. The system can comprise a light amplification element and a charge transport element.
K Tube Technology Llc


03/26/15
20150083355 

Fibrous pulp and use thereof in a composite


A composition comprises (i) an elastomer, (ii) from 1 to 5 volume % of fibrous pulp, the pulp having a specific surface area of from 7 to 11 sq.m./g and the fiber having a fiber length of from 0.5 to 1.1 mm, a tensile modulus of from 2.5 to 130 gpa, and a tensile strength of from 1 to 3 gpa, and (iii) from 5 to 14 volume % of yield-strain promoter in the form of fibers, needles, powder or platelets, wherein the composition has a yield strain of at least 70%, an elongation at break of at least 200%, and a yield stress of at least 4 mpa.. .
E I Du Pont De Nemours And Company


03/19/15
20150080300 

Growth factor concentrate and the use thereof


Provided herein are growth factor concentrates, cosmetic compositions and methods for cosmetic treatment. The growth factor concentrates comprise decapsulated growth factors derived from platelet rich plasma..
Bestop Group Holdings Limited


03/19/15
20150079194 

Systems, compositions, and methods for transplantation and treating conditions


Systems and methods for purification and concentration of autologous alpha-2 macroglobulin (a2m) from whole blood and or recombinant a2m are provided. Also provided are methods of treating wounds with a2m.
Cytonics Corporation


03/19/15
20150079169 

Controlled dosing of clopidogrel with gastric acid inhibition therapies


The present invention provides for novel formulations of clopidogrel in combination with proton pump inhibitors (ppi) and optionally with nsaids, for use as improved antiplatelet therapies in stroke and cardiovascular indications. The invention provides the delivery of clopidogrel in pulses or waves, such that the total dose is phased/spread out over time and, advantageously, combined with omeprazole in a way to minimize the conflicting actions these two drugs may have on each other.
Pozen Inc.


03/19/15
20150079153 

Cell suspension and use thereof


The present invention provides for methods and devices suitable for producing a transplantable cellular suspension of living tissue suitable for promoting tissue regeneration in an epithelium-related procedure, as well as compositions produced therefrom. The cellular suspension can include viable and functioning cells at various stages of differentiation, including undifferentiated/progenitor cells and differentiated cells, as well as those in between.
Avita Medical Ltd.


03/19/15
20150079142 

Devices and methods for preventing platelet activation


Methods for inhibiting a biomaterial-associated thrombotic event comprise reducing the number of platelets that bind to the biomaterial, or inhibiting platelet activation, by attaching cd47 or the ig domain thereof to the surface of the biomaterial. Methods of the present invention inhibit thrombi formation on or near a biomaterial that is on the surface of an implant, medical device, tube, or therapeutic delivery vehicle.
The Children's Hospital Of Philadelphia


03/19/15
20150079045 

Nprcps, pfdncs and uses thereof


Identification of a group of novel particle termed “non-platelet rna-containing particles (nprcp)” provides novel compositions, downstream products and therapeutic tools. In addition a group of mixed nprcps were identified that contain rnas and proteins.

03/19/15
20150075740 

Processes for clay exfoliation and uses thereof


The present invention provides methods for producing exfoliated clay platelets from a swellable clay material. In embodiments, the method for producing exfoliated clay platelets includes providing an exfoliating agent comprising an anionic extractant, and exposing the swellable clay material to the exfoliating agent, wherein the exfoliating agent produces exfoliated clay platelets from the swellable clay material.
Nanopaper, Llc


03/05/15
20150065374 

Detection of platelet-derived shed cd31


The present invention relates to various soluble forms of cd31, including a novel form which is shed by activated platelets and released into the circulation. Methods for detecting said soluble forms of cd31 are disclosed, as are methods of specifically 1 detecting said platelet-derived shed cd31 and the use of such methods as a diagnostic tool..
Assistance Publique-hopitaux De Paris


03/05/15
20150064800 

Diagnostic devices, methods and systems for detecting platelet factor 4 (pf4)/heparin antibodies


The present invention provides a novel assay for detecting human antibodies specific for a platelet factor 4 (pf4)/heparin complex in a fluid sample. The assay utilizes an immobilized pf4/polyanion complex and an anti-human antibody conjugated to a non-particulate fluorescent dye to capture and detect human pf4/heparin antibodies.

03/05/15
20150064687 

Method and producing platelet rich plasma


A device and method for producing a portion of platelet rich plasma from a fluid sample obtained from a patient. The device comprises three intercommunicated portions, each portion having an internal chamber defined therein.

03/05/15
20150064238 

Method and composition for enhancing the delivery of anti-platelet drugs for the treatment of acute stroke


The invention provides a method for enhancing the delivery of an anti-platelet drug for the treatment of acute stroke, comprising delivering a composition comprising an anti-platelet drug and a vehicle that can reduce the binding rate of plasma proteins, so that the anti-platelet drug can achieve the effect of treating acute stroke at a low dose. By use of the neuro-protective efficacy of anti-platelet drug, the invention allows the drug to release slowly to the site of treatment by combining anti-platelet drugs with a vehicle that can reduce the binding rate of plasma proteins to effectively reduce the dose of the anti-platelet drug and consequently reduce the side effects such as hypotension caused by, administration of a high dose of the anti-platelet drugs.

03/05/15
20150064202 

Humanized and chimeric anti-factor c3 antibodies and uses thereof


A method of inhibiting complement activation mediated by c3b inhibitors in a subject includes administering a c3b inhibitor to the subject to inhibit at least one of c3b binding to factors b and properdin, inhibit c3 cleavage, inhibit the activation of neutrophils, monocytes, platelets, and endothelium; or inhibit the formation of c3a, c5a, and mac.. .
Novelmed Therapeutics, Inc.


03/05/15
20150064133 

Bioactive compositions derivable from platelet concentrates, and methods for preparing and using same


The present disclosure provides a composition comprising a bioactive fraction derived from a platelet concentrate, methods of making the bioactive fraction, and culture medium supplemented with the bioactive fraction. Preferred bioactive fractions have relatively low fibrinogen concentrations while retaining native growth factors in beneficial amounts and ratios..
Cook General Biotechnology Llc




Popular terms: [SEARCH]

Platelet topics: Growth Factor, Fibroblast, Nanoparticle, Autologous, Leukocytes, Circulation, Transforming Growth Factor, Therapeutical, Platelet Derived Growth Factor, Bone Morphogenetic Protein, Endothelial, Recombinant, Stem Cells, Respiratory System, Dispensing System

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Platelet for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Platelet with additional patents listed. Browse our RSS directory or Search for other possible listings.


1.3371

4807

3 - 0 - 103